KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Cost of Revenue: 2011-2023

Historic Cost of Revenue for TherapeuticsMD (TXMD) over the last 12 years, with Sep 2023 value amounting to $106,000.

  • TherapeuticsMD's Cost of Revenue fell 70.06% to $106,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $1.5 million, marking a year-over-year increase of 101.80%. This contributed to the annual value of $1.4 million for FY2022, which is 0.36% down from last year.
  • According to the latest figures from Q3 2023, TherapeuticsMD's Cost of Revenue is $106,000, which was down 70.06% from $354,000 recorded in Q3 2022.
  • TherapeuticsMD's Cost of Revenue's 5-year high stood at $110.8 million during Q4 2019, with a 5-year trough of -$84.8 million in Q4 2021.
  • Over the past 3 years, TherapeuticsMD's median Cost of Revenue value was $524,500 (recorded in 2022), while the average stood at $363,125.
  • As far as peak fluctuations go, TherapeuticsMD's Cost of Revenue surged by 11,551.33% in 2019, and later tumbled by 426.17% in 2021.
  • TherapeuticsMD's Cost of Revenue (Quarterly) stood at $110.8 million in 2019, then crashed by 76.53% to $26.0 million in 2020, then tumbled by 426.17% to -$84.8 million in 2021, then tumbled by 98.82% to $354,000 in 2022, then tumbled by 70.06% to $106,000 in 2023.
  • Its last three reported values are $106,000 in Q3 2023, $354,000 for Q3 2022, and $348,000 during Q2 2022.